Prognostic Factors and Treatment Outcomes in Patients with Uterine Sarcoma in Turkey

Uterine sarcomas account for 1% of female genital tract cancers and 2-5% of uterine malignancies (Major et al., 1993; Tavassoli & Devilee, 2003). This heterogenous group of tumors derives from uterine mesodermal tissue and because of their rarity and histopathological diversity, there is a lack of consensus on prognostic factors and optimal treatment. Uterine sarcomas were classified into 4 main types: malignant mixt mullerian tumors (MMMT), accounting 40% of cases, also called carcinosarcomas, leiomyosacomas (LMS, 40% of cases), endometrial stromal sarcomas (ESS, 10-15% of cases) and undiferentiated sarcomas (5-10% of cases). Recently, many authors have proposed that MMMT should be classified as a subtype of endometrial carcinoma, due to the fact that their clinical behaviour looks like carcinoma (lymphatic dissemination pattern and response to platinum based chemotherapy) (Sleijfer et al., 2007). But MMMT behave more aggressively than endometrial